Role of ixabepilone in metastatic breast cancer treatment: Review and clinical case
https://doi.org/10.33667/2078-5631-2022-5-54-59
Abstract
This article reviews different aspects of usage of ixabepilone: from mechanism of action and data of clinical trials to clinical recommendations. We also present our own experience with this drug, which illustrates additional opportunities for extending survival in patient with metastatic breast cancer after seven lines of therapy. Rational usage of all available drugs helps to expand our treatment horizons and prolong lifetime of our patients.
About the Authors
I P. Ganshina
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Ganshina Inna P., PhD Med, leading researcher of Dept of Chemotherapy No. 1
Moscow
O. O. Gordeeva
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Gordeeva Olga O., PhD Med, oncologist of Dept of Chemotherapy No. 4
Moscow
E. V. Artamonova
National Medical Research Centre of Oncology n. a. N. N. Blokhin; Russian National Research Medical University n. a. N. I. Pirogov; Moscow Regional Research Clinical Institute named after M. F. Vladimirsky
Russian Federation
Russian Federation
Artamonova Elena V., DM Sci (habil.), head of Dept of Chemotherapy No. 1,
professor at Dept, head of Dept of Oncology and Thoracic Surgery
Moscow
References
1. Fojo A. T., Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005; 32: S 3–8.
2. Orr G. A., Verdier-Pinard P., McDaid H., Horwitz S. B. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003; 22: 7280–95.
3. Kowalski R. J., Giannakakou P., Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (TaxolR). J Biol Chem1997; 272: 2534–41.
4. McDaid H.M., Mani S., Shen H..J et al. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 2002; 8: 2035–43.
5. Lee F. Y.F., Castaneda S., Inigo I., Kan D., Paul B., Wen M.-L., et al. (2005) Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER 2 dependent breast cancers and is accompanied by modulation of molecular response markers. J Clin Oncol 23 (16 Suppl): 561–561 [Google Scholar].
6. Lee F. Y.F., Covello K. L., Castaneda S., Hawken D. R., Kan D., Lewin A., et al. (2008b) Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Caner Res 14: 8123–8131 [PubMed] [Google Scholar].
7. Lee F. Y.F., Smykla R., Johnston K., Menard K., McGlinchey K., Peterson R. W., et al. (2009b) Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 63: 201–212 [PubMed] [Google Scholar].
8. Roche H., Yelle L., Cognetti F., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.J Clin Oncol 2007; 25: 3415–20.
9. Denduluri N., Low J. A., Lee J. J., et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25: 3421–7.
10. Low J. A., Wedam S. B., Lee J. J., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23: 2726–34.
11. Thomas E., Tabernero J., Fornier M., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone b analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25: 3399–406.
12. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.J Clin Oncol 2007, 25: 3407–3414.
13. Thomas E. S., Gomez H. L., Li R. K.., Chung H. C., Fein L. E., Chan V. F., Jassem J., Pivot X. B.., Klimovsky J. V., de Mendoza F. H., Xu B., Campone M., Lerzo G. L., Peck R. A., Mukhopadhyay P., Vahdat L. T., Roché H. H. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20; 25 (33): 5210–7. DOI: 10.1200/JCO.2007.12.6557. Epub 2007 Oct 29. PMID: 17968020.
14. Hortobagyi G. N., Gomez H. L., Li R. K., Chung H. C., Fein L. E.., Chan VF., Jassem J., Lerzo G. L., Pivot X. B., Hurtado de Mendoza F., Xu B., Vahdat L. T., Peck R. A., Mukhopadhyay P, Roché H. H. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010 Jul; 122 (2): 409–18. DOI: 10.1007/s10549–010–0901–4. Epub 2010 May 8. PMID: 20454927.
15. Sparano J. A., Vrdoljak E., Rixe O., Xu B., Manikhas A., Medina C., Da Costa S. C., Ro J., Rubio G., Rondinon M., Perez Manga G., Peck R., Poulart V., Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010 Jul 10; 28 (20): 3256–63. DOI: 10.1200/JCO.2009.24.4244. Epub 2010 Jun 7. PMID: 20530276; PMCID: PMC 2903325.
16. Rugo H. S., Roche H., Thomas E., Chung H. C., Lerzo G. L., Vasyutin I., Patel A., Vahdat L. Efficacy and Safety of Ixabepilone and Capecitabine in Patients with Advanced Triple-negative Breast Cancer: A Pooled Analysis from Two Large Phase III, Randomized Clinical Trials. Clin Breast Cancer. 2018 Dec; 18 (6): 489–497. DOI: 10.1016/j.clbc.2018.07.024. Epub 2018 Aug 4. PMID: 30153978.
17. Osborne C., Challagalla J. D., Eisenbeis C. F., Holmes F. A., Neubauer M. A., Koutrelakos N. W., Taboada C. A., Vukelja S. J., Wilks S. T., Allison M. A., Reddy P., Sedlacek S., Wang Y., Asmar L., O’Shaughnessy J. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER 2-neu Negative and Triple Negative Metastatic Breast Cancer. Clin Breast Cancer. 2018 Feb; 18 (1): e89–e95. DOI: 10.1016/j.clbc.2017.07.002. Epub 2017 Jul 10. PMID: 28779904.
18. Tolaney S. M., Najita J., Sperinde J., Huang W., Chen W. Y., Savoie J., Fornier M., Winer E. P., Bunnell C., Krop I. E. A phase II study of ixabepilone and trastuzumab for metastatic HER 2-positive breast cancer. Ann Oncol. 2013 Jul; 24 (7): 1841–1847. DOI: 10.1093/annonc/mdt121. Epub 2013 Apr 4. PMID: 23559151; PMCID: PMC 3690910.
19. Moulder S., Li H., Wang M., Gradishar W. J., Perez E. A., Sparano J. A., Pins M., Yang X., Sledge G. W. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER 2-positive metastatic breast cancer: an Eastern Cooperative On- cology Group Trial. Breast Cancer Res Treat. 2010 Feb; 119 (3): 663–71. DOI: 10.1007/s10549–009–0658–9. PMID: 20012354; PMCID: PMC 3133687.
20. Roché H., Conte P., Perez E. A., Sparano J. A., Xu B., Jassem J., Peck R., Kelleher T., Hortobagyi G. N. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat. 2011 Feb; 125 (3):755–65. DOI: 10.1007/s10549–010–1251-y. Epub 2010 Dec 3. PMID: 21128114.
21. Vahdat L. T., Vrdoljak E., Gómez H., Li R. K., Bosserman L., Sparano J. A., Baselga J., Mukhopadhyay P., Valero V. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. J Geriatr Oncol. 2013 Oct; 4 (4): 346–52. DOI: 10.1016/j.jgo.2013.07.006. Epub 2013 Aug 23. PMID: 24472478.
22. Valero V., Vrdoljak E., Xu B., Thomas E., Gómez H., Manikhas A., Medina C., Li R. K., Ro J., Bosserman L., Vahdat L., Mukhopadhyay P., Opatt D., Sparano J. A. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer. 2012 Aug; 12 (4): 240–6. DOI: 10.1016/j.clbc.2012.03.013. Epub 2012 Jun 2. PMID: 22658378.
23. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022065TOC.cfm
24. Tyulyandin S. A., Zhukova L. G., Koroleva I. A., Parokonnaya A. A., Semiglazova T. Yu., Stenina M. B. et al. Practical recommendations for drug treatment of breast cancer. Malignant Tumors: Practice Guidelines RUSSCO #3s2, 2021 (vol. 11).
25. Recommendations of Russian oncologists, ed. Academician A. D. Caprina ‘Breast Cancer’ from 02/01/2020.
26. NCCN Guidelines ‘Breast Cancer’, Version 02.2022.
27.
Review
For citations:
Ganshina I.P., Gordeeva O.O., Artamonova E.V. Role of ixabepilone in metastatic breast cancer treatment: Review and clinical case. Medical alphabet. 2022;1(5):54-59. (In Russ.) https://doi.org/10.33667/2078-5631-2022-5-54-59
Views:
311
Email this article 